POLE and colorectal carcinoma: Furthermore, mutations of POLE or POLD1 were detected in approximately 47% (8/17) of the NTRK+ CRC subset and more than half of the patients (5/8) carried concurrent POLE/POLD1 mutations including missense and truncating variants (Figure 2B).